Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2

BACKGROUND: Meningiomas occur in 80% of persons with neurofibromatosis 2 (NF2) and cause significant mortality and morbidity, yet there are no effective medical treatments. NF2-deficient tumors have constitutive activation of mammalian/mechanistic target of rapamycin (mTOR), and treatment with mTORC...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, Justin T, Orr, Christina C, Thalheimer, Raquel D, Cambillo, Josephine V, Beauchamp, Roberta L, Shaikh, Ghalib, Muzikansky, Alona, Stemmer-Rachamimov, Anat, Giovannini, Marco, Kalamarides, Michel, Barker, Fred G, Ramesh, Vijaya, Plotkin, Scott R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195194/
https://www.ncbi.nlm.nih.gov/pubmed/37215956
http://dx.doi.org/10.1093/noajnl/vdad041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195194/
https://www.ncbi.nlm.nih.gov/pubmed/37215956
http://dx.doi.org/10.1093/noajnl/vdad041

Ejemplares similares